Nested Therapeutics key facts
- Operator of a medical research firm intended to develop precision oncology medicine therapies by finding new driver mutations.
- Nested Therapeutics’s last known valuation is $203.2M.
- It has raised $128.2M; the latest was Early Stage VC ($3.2M) in Aug 2024.
- Notable investors include Blue Owl Capital, S32, Foresite Capital, Avidity Partners, Versant Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Nested Therapeutics: the Monday email on marks, rounds and moves
Nested Therapeutics funding rounds
No funding rounds for Nested Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Nested Therapeutics valuation
Nested Therapeutics's last known valuation is $203 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Nested Therapeutics investors
8 investors are on record for Nested Therapeutics, including Blue Owl Capital, S32, Foresite Capital and Avidity Partners.
About Nested Therapeutics
Operator of a medical research firm intended to develop precision oncology medicine therapies by finding new driver mutations. The company discovers novel, targeted, small-molecule precision oncology medicine by using mutation clusters to identify druggable pockets with a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI, enabling healthcare professionals to better treat patients with precision medication.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 19
- Website
- nestedtx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Nested Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.